Overview

• Carnegie Mellon’s Feinberg lab has developed a fully collagen-based bioprinting technique, enabling the creation of vascularized tissue systems with 100-micron resolution.
• The FRESH bioprinting method produced centimeter-scale pancreatic-like tissues capable of glucose-stimulated insulin release, surpassing organoid-based approaches.
• FluidForm Bio, a Carnegie Mellon spinout, has demonstrated the technology's potential to cure type 1 diabetes in animal models and plans to begin human clinical trials.
• The research team's findings were published in *Science Advances*, showcasing advancements in biologic tissue modeling for regenerative medicine and disease study.
• Open-source designs for the technology are being prepared to encourage global research adoption and further innovation across various disease and tissue areas.